Ophthalmoscopes Focused Insights 2024-2029 with Baxter, Halma, HEINE Optotechnik, IRIDEX, Rudolf Riester, Nidek, and Zumax Medical Dominating the $86.87 Billion Market
05 nov. 2024 07h53 HE
|
Research and Markets
Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) -- The "Ophthalmoscopes Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Ophthalmoscopes Market was valued...
Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China
29 juil. 2024 16h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET
22 juil. 2024 12h00 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery
27 juin 2024 07h05 HE
|
Clearside Biomedical, Inc.
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in...
Global Nonmydriatic Handheld Fundus Cameras Strategic Research Report 2024: Market to Reach $259 Million by 2030 - Glaucoma Prevalence and Need for Screening to Fuel Sales
23 mai 2024 11h08 HE
|
Research and Markets
Dublin, May 23, 2024 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Nonmydriatic...
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
21 mai 2024 07h05 HE
|
Clearside Biomedical, Inc.
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support...
Global Uveitis Treatment Research Report 2024: Market to Reach $1.34 Billion by 2034, Fueled by Increased Prevalence, Treatment Improvements, and Strategic Alliances & Collaborations
16 mai 2024 10h30 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Global Uveitis Treatment Market" report has been added to ResearchAndMarkets.com's offering.The global uveitis treatment market accounted for USD 753...
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast...
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
08 mai 2024 16h15 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 mars 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...